BHC · Bausch Health Companies Inc.
$4.51
+0.03 (+0.67%)
At close · Jul 28
Market Cap
$1.67B
Shares
373.48M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.48
Open$4.48
Day$4.47–4.60
52W$4.33–8.69
Avg vol 30d2.6M
Short int7.4M · 2.0% float · 3.7d
Short vol69%
Last earningsApr 29, 2026
DataJan 2020–Jul 2026
Filing10-Q · Apr 30
Up next
Next earnings call
Jul 29, 2026
Est · unconfirmed
· this week
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−11%
below
RSI (14)
37
neutral
MACD trend
Negative
52-week position
3%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−22%
trailing
YTD return
−36%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Distributing
41 of 231 funds reported for Jun 30 · net -157.6K sh shares · +1 new
Insider flow
Distributing
Net -$132.8K over 90 days · 100% sells
Short interest
Rising
1.97% of float · ▲ +0.5% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
231 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
−10%
Y/Y
EPS growth
+423%
Y/Y
Free cash flow
$1.0B
Balance sheet
$19.5B
net debt
Quant / Vol
risk profile
Volatility
50%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 30, 2025
Revenue
· full year
Initiated
$5B – $5.1B
prior FY $10.27B
midpoint −50.8% Y/Y
Adjusted EBITDA (excluding the impact of core IP R&D)
· full year
Initiated
$2.7B – $2.75B
Adjusted operating cash flow
· full year
Initiated
$975M – $1.03B
Guided vs delivered
· last 1 settled
Revenue
full year
guided $5B – $5.1B
$10.27B
Beat +103.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
37
Neutral
MACD trend
Negative
Bearish
52-week position
3%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $5 › 200d $6 — 200d above 50d
Institutional flow
Distributing
41 of 231 funds reported for Jun 30 · net -157.6K sh shares · +1 new
Insider flow
Distributing
Net -$132.8K over 90 days · 100% sells
Short interest
Rising
1.97% of float · ▲ +0.5% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
231 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $4
Now $4 · 3%
52-wk high $9
vs 200-day avg -24%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP) non-GAAP | $837M | first quarter of 2026 | — |
|
|
|||
| Consolidated Adjusted Net Income Attributable to Bausch Health (non-GAAP) non-GAAP | $296M | first quarter of 2026 | — |
| Adjusted Cash Flow from Operations non-GAAP | $1.2B | Full-Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BHC
this stock
Bausch Health Companies Inc.
|
$1.67B | -35.5% | -9.8% | — | 2.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$55.69B | +11.9% | — | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$51.90B | — | — | — | 0.0% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.77B | -1.7% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BHC | -7.3% | -15.2% | -22.0% | -9.1% | -35.5% |
| SPY | -0.6% | +0.7% | +6.8% | -1.0% | +8.4% |
| vs SPY | -6.7% | -15.8% | -28.8% | -8.1% | -43.9% |
Key facts
CIK
885590
CUSIP
071734107
13F (30d)
32 filings
32 filers
Visit website
Investor relations